ArticleBioinformatics (Oxford, England)2026
PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationThe identification of protective antigens is fundamentally constrained by sparse annotations and pervasive label uncertainty in reverse vaccinology. Protective antigen-antibody interactions are mediated by a limited subset of surface-accessible residues that form spatially coherent epitopes. This motivates modeling antigenicity at the residue level, where 3D structure provides critical context for functional immune recognition. Moreover, antigen datasets are inherently positive unlabeled: unannotated proteins may contain hidden positives, making reliable negatives difficult to obtain.
resultsWe present PU-GRAIL, a graph neural network framework that integrates protein language model embeddings with predicted 3D structures under positive-unlabeled learning. Trained and evaluated on three benchmark datasets, PU-GRAIL achieves competitive performance compared with existing methods. Importantly, the model's attention mechanism enables residue-level interpretation, identifying putative epitope regions that correspond to experimentally validated antibody-binding sites. Beyond standard benchmarks, we demonstrate practical utility through (i) severity-associated antigenicity patterns in SARS-CoV-2 patient cohorts, and (ii) proteome-wide vaccine candidate prioritization across 11 bacterial species. AVAILABILITY AND IMPLEMENTATION: The PU-GRAIL software is available at https://github.com/jaeminjj/PU-GRAIL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.